Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Endocrine Disorder Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IGF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IGF1 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View IGF1 Products |
| Gene Delivery | IGF1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IGF1 Products |
| Benchmark Ab | Anti-IGF1 (Sequence of Xentuzumab) Recombinant positive control. |
View IGF1 Products |
| Validator | IGF1 siRNA Set For knockdown verification. |
View IGF1 Products |
| Related Target A | IGF1R Primary receptor mediating mitogenic and anti-apoptotic signaling pathways. |
View IGF1R Products |
| Related Target B | IGFBP3 Major carrier protein regulating IGF1 bioavailability and receptor interaction. |
View IGFBP3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-reactivity screening (Insulin & IGF2) | Human IGF1, IGF2, and Insulin proteins strictly verified by mass spectrometry and high-purity HPLC. |
| IGFBP interference profiling | Active recombinant IGFBP panel (IGFBP1-6) available for competitive binding assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live IGF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IGF1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and ligand traps that simultaneously neutralize IGF1 and IGF2. As first-generation therapies reach the clinic, the next wave of R&D is targeting overcoming resistance to EGFR inhibitors and hormone therapies in solid tumors, as well as addressing rare endocrine indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody / Ligand Trap | Boehringer Ingelheim, Pierre Fabre | Solid Tumors (Breast, Prostate) | Neutralization Assay (Need high-purity ligand and receptor proteins) |
| Recombinant Protein / Agonist | Ipsen, Tercica | Growth Hormone Insensitivity | Conformational Stability (Need sequence-verified, high-purity standards) |
| Bispecific / Multi-specific | Innovent, Roche | Oncology Resistance Pathways | Selectivity Screening (Need cross-reactive and related target panels) |